Ascletis Pharma has received FDA IND clearance to begin a Phase II study of ASC30 in type 2 diabetes. This marks a key expansion of ASC30 beyond obesity into the much larger diabetes market.
Phase II Diabetes Trial: Study Design at a Glance
The upcoming study is a 13-week, randomized, double-blind, placebo-controlled, multi-center trial in the U.S.
Key details:
- ~100 adults with type 2 diabetes mellitus
- Enrollment expected to start Q1 2026
- Once-daily oral ASC30 tablets
Dose allocation:
- 40 mg, 60 mg, and 80 mg ASC30
- Matching placebo
- Randomization ratio: 2:3:3:2
ASC30 will be titrated weekly from 1 mg to target doses.
Primary and Secondary Endpoints
Primary endpoint
- Mean change in HbA1c from baseline at 13 weeks versus placebo
Secondary endpoints
- Change in fasting blood glucose
- Change in body weight
- Safety and tolerability outcomes
Strong Phase II Obesity Data De-Risk the Program
Ascletis recently completed a 13-week U.S. Phase II study of ASC30 in obesity or overweight. Results were both clinically meaningful and dose-dependent.
Placebo-adjusted weight loss at 13 weeks:
- 5.4% at 20 mg
- 7.0% at 40 mg
- 7.7% at 60 mg
No weight-loss plateau was observed.
Gastrointestinal Tolerability Stands Out
ASC30 showed favorable GI tolerability compared with other oral GLP-1s.
Key safety highlights:
- Vomiting rate was ~50% lower than published data for orforglipron with weekly titration
- GI tolerability comparable to orforglipron titrated every four weeks in Phase III
- No hepatic safety signal
- Discontinuation due to adverse events: 4.8%
What Makes ASC30 Different?
ASC30 is a small-molecule, fully biased GLP-1 receptor agonist, discovered and developed in-house.
Differentiation points:
- Once-daily oral dosing
- Potential for monthly or quarterly subcutaneous dosing
- Designed for obesity, diabetes, and broader metabolic disease use
Management Commentary
“IND clearance for this Phase II diabetes study is a significant milestone,” said Dr. Jinzi Jason Wu, Founder and CEO of Ascletis.
“The FDA clearance expands ASC30’s clinical development into the large diabetes treatment market.”
Why This Matters?
Oral GLP-1s remain one of the most competitive drug classes in pharma.
ASC30’s profile suggests:
- Competitive weight loss
- Improved tolerability
- Flexible dosing potential
If Phase II diabetes data hold up, ASC30 could become a serious contender in metabolic disease therapy.
